Life Biosciences, the company co-founded by Harvard Medical School geneticist David Sinclair, has released the first human data for ER-100, a gene therapy designed to partially reprogram aging cells in the eye6. In three people with open-angle glaucoma who received the lowest dose, the company reported no dose-limiting toxicities, serious adverse events or adverse events of special interest through Day 56, and visual field improvements in two of the three1. The interim results were presented on 8 October 2026 at Eyecelerator, a meeting held alongside the American Academy of Ophthalmology annual meeting in New Orleans3.
The data come from an open-label Phase 1 study with no placebo group, and they have not been published in a peer-reviewed journal24. Life Biosciences describes ER-100 as the first therapy based on partial epigenetic reprogramming to reach human clinical trials7.
What happened
ER-100 is given as a single injection into the vitreous, the gel inside the eye. It carries genes for three transcription factors, OCT4, SOX2 and KLF4, known together as OSK, and the company says the goal is to reset the epigenetic code of retinal ganglion cells toward more youthful patterns of gene expression1. The genes are switched on by the antibiotic doxycycline, which participants take by mouth daily for eight weeks. They also receive a tapering course of the steroid prednisolone, intended to limit inflammation from an immune response to the AAV-2 viral vector that delivers the genes1.
The first three participants, all with open-angle glaucoma, received Dose Level 1, 2×10¹¹ vector genomes (vg). After reviewing their safety data, the trial's Data Safety Monitoring Board recommended escalating to Dose Level 2, 6×10¹¹ vg15. Doses are reported here only to describe the study.
On 1 October the company announced that its chief scientific officer, Sharon Rosenzweig-Lipson, would present the data in the meeting's glaucoma session3. In that announcement she described the aim of the program:
"we are testing whether we can restore these cells to a more youthful state, not just slowing vision loss but potentially reversing it."
Source:3
The evidence so far
Everything below comes from the company's announcement and the conference presentation it summarizes1.
| Measure | Reported result |
|---|---|
| Participants | 3, all with open-angle glaucoma |
| Dose | Dose Level 1, 2×10¹¹ vg, single intravitreal injection |
| Follow-up | Day 56 |
| Dose-limiting toxicities, serious adverse events, adverse events of special interest | None reported |
| Other adverse events | Attributed by the company to the injection procedure, the steroid or pre-existing conditions |
| Humphrey Visual Field | 2 of 3 improved: at least 28% of tested points better by more than 4 dB |
Source:1
The visual field results are the headline number, but the company itself frames them as preliminary observations from a study built to assess safety and tolerability15. Coverage by Pharmacally noted that no improvement was reported for the third participant4.
Rosenzweig-Lipson said the results "provide early information regarding the tolerability" of the therapy and are "encouraging as we continue to advance the ER-100 program"1.
What it does not show yet
- Whether ER-100 caused the changes. The study is non-randomized and unmasked2. With no control group, changes in vision cannot be attributed to the therapy, and the reported findings "do not establish treatment efficacy," as Pharmacally put it4.
- Whether the gains are real and lasting. Visual field testing varies from one session to the next, which could influence results in a sample this small4. Durability beyond 56 days is unknown4.
- Long-term safety. The registry lists follow-up through Year 5, including vision, immune response markers and viral shedding2. Three people over eight weeks cannot reveal rare or delayed effects.
- Results in NAION. No data have been reported for non-arteritic anterior ischemic optic neuropathy. The registry plans a NAION cohort at a dose chosen from the glaucoma data2.
- Independent review. The data have been released by the company and presented at a conference, not published in a peer-reviewed paper.
Who is behind it
Life Biosciences sponsors the trial (NCT07290244), which the registry lists as recruiting at sites in Glendale, California; Boston; New York; and Charleston, South Carolina, with an estimated enrollment of 18 adults aged 40 to 852. Coverage of the trial design describes those 18 as 12 people with glaucoma and 6 with NAION4.
Sinclair is a co-founder of the company. When the first patient was dosed, he said that aging research "has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage"6. That idea underpins ER-100, and readers should weigh the results with the knowledge that the company and its founders have a direct interest in the program.
In April 2026 the company raised an $80 million Series D. It said the money would fund operations through the second half of 2027, including completion of the ER-100 Phase 1 trial9.
How it fits the field
The scientific starting point is animal work. In a 2020 Nature paper from Sinclair's lab, expressing Oct4, Sox2 and Klf4 in retinal ganglion cells of mice restored youthful DNA methylation patterns and gene activity, promoted nerve fiber regrowth after injury and reversed vision loss in aged mice and in a mouse glaucoma model8. Those were mouse results.
Life Biosciences has since reported nonhuman primate studies showing controlled OSK expression, restored methylation patterns and improved visual function after injection into the eye7. Those are also animal results, reported by the company.
The program has moved quickly through regulatory steps in 2026:
| Date | Milestone |
|---|---|
| 28 Jan 2026 | FDA clears the IND application7 |
| 2 Mar 2026 | Study start date listed in registry2 |
| 8 Apr 2026 | $80 million Series D9 |
| 9 Jun 2026 | First patient dosed announced6 |
| 8 Oct 2026 | Interim data from first 3 glaucoma patients1 |
Current glaucoma treatments target risk factors such as eye pressure but do not repair damaged retinal ganglion cells, and NAION has no approved treatment, according to the company6. That unmet need is why an eye disease, rather than aging itself, is the first test of the approach.
What to watch next
- Safety and visual field data from the Dose Level 2 cohort at 6×10¹¹ vg1.
- Whether the NAION cohort opens, and at what dose2.
- The registry's estimated primary completion date of May 20272.
- A peer-reviewed publication with full data, including results for each participant and test-retest context for the visual field changes.
- Any longer-term follow-up on immune responses to the AAV-2 vector, which the trial is tracking2.
For now, the result is that three people tolerated the lowest dose for eight weeks without serious problems reported by the company, and the trial is moving to a higher dose. Whether reprogramming cells in the eye can restore vision is still an open question.
